Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059

Blood

Volumn 129, Issue 20, 2017, Pages 2808-2810

  Walter, Harriet S ^a   Jayne, Sandrine ^a   Rule, Simon A ^b   Cartron, Guillaume ^c   Morschhauser, Franck ^d,e   Macip, Salvador ^a   Karlin, Lionel ^f   Jones, Ceri ^g   Herbaux, Charles ^d,e   Quittet, Philippe ^c   Shah, Nimish ^b   Hutchinson, Claire V ^a,b   Fegan, Christopher ^g   Yang, Yingsi ^h   Mitra, Siddhartha ^h   Salles, Gilles ^f   Dyer, Martin J S ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d Univ Lille   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ LYON 1   (France)

^g CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^h GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACALABRUTINIB; ANTINEOPLASTIC AGENT; BGB 3111; BRUTON TYROSINE KINASE INHIBITOR; IBRUTINIB; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; NOTCH1 RECEPTOR; ONO GS 4059; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; GS-4059; IMIDAZOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADVERSE OUTCOME; ANEMIA; ANTICOAGULANT THERAPY; ARTHRALGIA; ATRIAL FIBRILLATION; BASAL CELL CARCINOMA; BRONCHITIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; COUGHING; DIARRHEA; DISEASE COURSE; DNA BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FALLING; FATIGUE; FEVER; FOLLOW UP; GENE MUTATION; HEMATOMA; HERPES ZOSTER; HUMAN; HYPERTENSION; LETTER; LOWER ABDOMINAL PAIN; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTOSIS; MUSCULOSKELETAL PAIN; NEUTROPENIA; OROPHARYNX PAIN; OVERALL SURVIVAL; PARESTHESIA; PETECHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PURPURA; RHINOPHARYNGITIS; SIDE EFFECT; SKIN BRUISING; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; MALE; MORTALITY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SURVIVAL RATE;

EID: 85019690677     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-02-765115     Document Type: Letter

References (19)

1. Maddocks K, Jones JA. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. Semin Oncol. 2016;43(2):251-259.
2. Jeyakumar D, O'Brien S. B cell receptor inhibition as a target for CLL therapy. Best Pract Res Clin Haematol. 2016;29(1):2-14.
3. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
4. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
5. Smith MR. Ibrutinib in B lymphoid malignancies. Expert Opin Pharmacother. 2015;16(12):1879-1887.
6. Tucker DL, Rule SA. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Ther Clin Risk Manag. 2015; 11:979-990.
7. UK CLL Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016; 101(12):1563-1572.
8. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80-87.
9. Mato AR, Lamanna N, Ujjani CS, et al. Toxicities and outcomes of ibrutinibtreated patients in the united states: Large retrospective analysis of 621 real world patients [abstract]. Blood. 2016;128(22). Abstract 3222.
10. Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411-419.
11. Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323-332.
12. Tam CS, Opat S, Cull G, et al. Twice daily dosing with the highly specific BTK inhibitor, bgb-3111, achieves complete and continuous BTK occupancy in lymph nodes, and is associated with durable responses in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [abstract]. Blood. 2016;128(22). Abstract 642.
13. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-2506.
14. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810-1817.
15. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI- 32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-1189.
16. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
17. Foà R, Del Giudice I, Guarini A, Rossi D, Gaidano G. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica. 2013; 98(5):675-685.
18. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013;31(14):1767-1774.
19. Woyach J, Guinn D, Ruppert MAS, et al. The development and expansion of resistant subclones precedes relapse during ibrutinib therapy in patients with CLL [abstract]. Blood. 2016;128(22). Abstract 55.